# US 6,730,300 B2 · Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,300 B2
- Document ID: US6730300B2
- Status: Granted
- Kind: B2
- Application number: 09/155,106
- Filed: 1998-11-17
- Published: 2003-03-20
- Granted: 2004-05-04
- Earliest claimed: 1996-03-20
- Assignees: Immunomedics, Inc.
- Inventors: Shui-on Leung; Michele J. Losman; Hans Hansen
- Web page: https://patentgrep.com/patent/US6730300B2

## CPC

- C07K 16/3007: {Carcino-embryonic Antigens}
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- C07K 16/4266: {against anti-tumor receptor Ig}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A humanized form of an anti-idotype antibody to CEA, e.g., hW12, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idotype also can be used as an immunogenic vaccine.

## Claims

### Claim 1

An anti-idiotype antibody or an antigen binding fragment thereof, which specifically binds to the idiotype region of an anti-CEA monoclonal antibody, MN-14, wherein said anti-idiotypic antibody comprises the rat anti-idiotypic antibody (rWI2) light chain variable region comprising SEQ ID NO:22 and heavy chain variable region comprising SEQ ID NO: 18 derived from a rat antibody and constant regions selected from human antibody sequences.

### Claim 2 (depends on 1)

An antibody or fragment thereof according to claim 1, wherein said anti-idiotype antibody or antibody fragment is labeled with a radiolabel, an enzyme, or a fluorescent agent.

### Claim 3

A humanized anti-idiotype antibody or an antigen binding fragment thereof which specifically binds the idiotype region of an anti-CEA CEA monoclonal antibody, MN-14, wherein said humanized anti-idiotypic antibody comprises rat anti-idiotypic antibody (rWI2) CDRs, wherein the CDRs of the light chain variable region comprises:
the CDR-1 sequence, SEQ ID NO: 4, RASQDIGNYLR,
the CDR-2 sequence, SEQ ID NO: 5, GATNLAA, and
the CDR-3 sequence, SEQ ID NO: 6, LHHSEYPYT;
and, wherein the CDRs of the heavy chain variable region comprises:
the CDR-1 sequence, SEQ ID NO: 1, NYWMT,
the CDR-2 sequence, SEQ ID NO: 2, SITSTGGTYHAESVKG, and
the CDR-3 sequence, SEQ ID NO: 3, DDYGGQSTYVMDA;
and humanized framework regions.

### Claim 4 (depends on 3)

A humanized anti-idiotype antibody or fragment thereof according to claim 3, wherein the heavy chain variable region comprises the KOLWI2VH-1 or the KOLWI2VH-2 sequence, SEQ ID NOS: 19 or 20, respectively.

### Claim 5 (depends on 3)

A humanized anti-idiotype antibody or fragment thereof according to claim 3, wherein the light chain variable region comprises the REIWI2VK or the REIWI2VKRS sequence, SEQ ID NOS: 21 or 23, respectively.

### Claim 6 (depends on 3)

A humanized antibody or fragment thereof according to claim 3, wherein said anti-idiotype antibody or antibody fragment is labeled with a radiolabel, an enzyme, or a fluorescent agent.

### Claim 7 (depends on 1)

An immunogenic composition comprising the anti-idiotype antibody or antibody fragment of claim 1, conjugated to a soluble immunogenic carrier protein, for use in stimulating an immune response in a patient against a cancer characterized by expression of CEA.

### Claim 8 (depends on 3)

An immunogenic composition comprising the humanized anti-idiotype antibody or antibody fragment of claim 3, conjugated to a soluble immunogenic carrier protein, for use in stimulating an immune response in a patient against a cancer characterized by expression of CEA.

### Claim 9 (depends on 1)

A method of clearing an antibody or antibody fragment or conjugate thereof that specifically binds CEA, wherein said antibody or antibody fragment or conjugate Thereof has been administered to said patient, the method comprising subsequently administering to said patient an anti-idiotype antibody or fragment thereof according to claim 1 to clear non-targeted anti-CEA antibody or antibody fragment or conjugate thereof.

### Claim 10 (depends on 3)

A method of clearing an antibody or antibody fragment or conjugate thereof that specifically binds CEA, wherein said antibody or antibody fragment or conjugate thereof has been administered to said patient, the method comprising subsequently administering to said patient an anti-idiotype antibody or fragment thereof according to claim 3 to clear non-targeted anti-CEA antibody or antibody fragment or conjugate thereof.

### Claim 11 (depends on 8)

A method of stimulating an immune response in a patient against cancers expressing carcinoembryonic antigen, which comprises administering to said patient an effective amount of the immunogenic composition of claim 8, conjugated to a soluble immunogenic carrier protein, optionally in combination with a pharmaceutically acceptable adjuvant.

### Claim 12 (depends on 7)

A method of stimulating an immune response in a patient against cancers expressing carcinoembryonic antigen, which comprises administering to said patient an effective amount of the immunogenic composition of claim 7, conjugated to a soluble immunogenic carrier protein, optionally in combination with a pharmaceutically acceptable adjuvant.
